CN1161345C - 1,5-benzodiazepine derivatives as cck-A receptor agonists - Google Patents
1,5-benzodiazepine derivatives as cck-A receptor agonists Download PDFInfo
- Publication number
- CN1161345C CN1161345C CNB008099324A CN00809932A CN1161345C CN 1161345 C CN1161345 C CN 1161345C CN B008099324 A CNB008099324 A CN B008099324A CN 00809932 A CN00809932 A CN 00809932A CN 1161345 C CN1161345 C CN 1161345C
- Authority
- CN
- China
- Prior art keywords
- enantiomorph
- compound
- cck
- phenyl
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 108010089335 Cholecystokinin A Receptor Proteins 0.000 title description 5
- 102100034927 Cholecystokinin receptor type A Human genes 0.000 title description 5
- ZVAPWJGRRUHKGP-UHFFFAOYSA-N 1h-1,5-benzodiazepine Chemical class N1C=CC=NC2=CC=CC=C12 ZVAPWJGRRUHKGP-UHFFFAOYSA-N 0.000 title description 2
- 239000000018 receptor agonist Substances 0.000 title 1
- 229940044601 receptor agonist Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 59
- 238000002360 preparation method Methods 0.000 claims abstract description 27
- 238000000034 method Methods 0.000 claims abstract description 20
- 201000010099 disease Diseases 0.000 claims abstract description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 9
- 208000008589 Obesity Diseases 0.000 claims abstract description 7
- 235000020824 obesity Nutrition 0.000 claims abstract description 7
- 150000001412 amines Chemical class 0.000 claims description 32
- 239000000203 mixture Substances 0.000 claims description 29
- 238000006243 chemical reaction Methods 0.000 claims description 19
- 150000003839 salts Chemical class 0.000 claims description 14
- -1 p-methoxy-benzyl Chemical group 0.000 claims description 12
- 150000002923 oximes Chemical class 0.000 claims description 8
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 5
- 150000002148 esters Chemical class 0.000 claims description 5
- 229910052739 hydrogen Inorganic materials 0.000 claims description 4
- 125000006239 protecting group Chemical group 0.000 claims description 4
- 125000005982 diphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 3
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 3
- 206010012601 diabetes mellitus Diseases 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 208000020694 gallbladder disease Diseases 0.000 claims description 2
- 238000007327 hydrogenolysis reaction Methods 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 230000009467 reduction Effects 0.000 claims description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims 1
- BSCCSDNZEIHXOK-UHFFFAOYSA-N phenyl carbamate Chemical compound NC(=O)OC1=CC=CC=C1 BSCCSDNZEIHXOK-UHFFFAOYSA-N 0.000 claims 1
- 150000004986 phenylenediamines Chemical group 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 33
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 26
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 26
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 25
- 230000000694 effects Effects 0.000 description 21
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 20
- 239000007787 solid Substances 0.000 description 20
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 19
- 238000012360 testing method Methods 0.000 description 19
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 18
- 239000004480 active ingredient Substances 0.000 description 17
- 239000002904 solvent Substances 0.000 description 17
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 15
- 210000000232 gallbladder Anatomy 0.000 description 14
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 13
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
- 238000003756 stirring Methods 0.000 description 12
- 238000005406 washing Methods 0.000 description 12
- 101800001982 Cholecystokinin Proteins 0.000 description 11
- 102100025841 Cholecystokinin Human genes 0.000 description 11
- 229940107137 cholecystokinin Drugs 0.000 description 11
- 235000019439 ethyl acetate Nutrition 0.000 description 11
- 239000007788 liquid Substances 0.000 description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 9
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 9
- 239000000556 agonist Substances 0.000 description 9
- 239000000725 suspension Substances 0.000 description 9
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 8
- 108010087230 Sincalide Proteins 0.000 description 8
- 238000010609 cell counting kit-8 assay Methods 0.000 description 8
- 239000011541 reaction mixture Substances 0.000 description 8
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 7
- 235000019359 magnesium stearate Nutrition 0.000 description 7
- 239000012453 solvate Substances 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 6
- 239000011259 mixed solution Substances 0.000 description 6
- 210000000496 pancreas Anatomy 0.000 description 6
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 6
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 6
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 6
- 102000004859 Cholecystokinin Receptors Human genes 0.000 description 5
- 108090001085 Cholecystokinin Receptors Proteins 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 5
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 5
- 210000004556 brain Anatomy 0.000 description 5
- 238000004587 chromatography analysis Methods 0.000 description 5
- 239000012043 crude product Substances 0.000 description 5
- 239000008108 microcrystalline cellulose Substances 0.000 description 5
- 229940016286 microcrystalline cellulose Drugs 0.000 description 5
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 229940080313 sodium starch Drugs 0.000 description 5
- 235000014347 soups Nutrition 0.000 description 5
- 238000001291 vacuum drying Methods 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
- 102100021022 Gastrin Human genes 0.000 description 4
- 108010052343 Gastrins Proteins 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 230000003042 antagnostic effect Effects 0.000 description 4
- 239000005557 antagonist Substances 0.000 description 4
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 description 4
- 231100000673 dose–response relationship Toxicity 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 230000014759 maintenance of location Effects 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 4
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000012488 sample solution Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- LTMRRSWNXVJMBA-UHFFFAOYSA-L 2,2-diethylpropanedioate Chemical compound CCC(CC)(C([O-])=O)C([O-])=O LTMRRSWNXVJMBA-UHFFFAOYSA-L 0.000 description 3
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 108010089448 Cholecystokinin B Receptor Proteins 0.000 description 3
- 102100036016 Gastrin/cholecystokinin type B receptor Human genes 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 241001632427 Radiola Species 0.000 description 3
- 235000021355 Stearic acid Nutrition 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000003513 alkali Substances 0.000 description 3
- 235000019789 appetite Nutrition 0.000 description 3
- 230000036528 appetite Effects 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 229950005953 camsilate Drugs 0.000 description 3
- 239000003743 cholecystokinin B receptor antagonist Substances 0.000 description 3
- 238000013016 damping Methods 0.000 description 3
- 239000011928 denatured alcohol Substances 0.000 description 3
- 238000004821 distillation Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003480 eluent Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 229960004756 ethanol Drugs 0.000 description 3
- 238000011049 filling Methods 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 235000019253 formic acid Nutrition 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 125000000468 ketone group Chemical group 0.000 description 3
- 229960001375 lactose Drugs 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 235000021056 liquid food Nutrition 0.000 description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
- 229920000053 polysorbate 80 Polymers 0.000 description 3
- 238000002203 pretreatment Methods 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 229960001866 silicon dioxide Drugs 0.000 description 3
- 238000003153 stable transfection Methods 0.000 description 3
- 239000008117 stearic acid Substances 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- MEIRRNXMZYDVDW-MQQKCMAXSA-N (2E,4E)-2,4-hexadien-1-ol Chemical compound C\C=C\C=C\CO MEIRRNXMZYDVDW-MQQKCMAXSA-N 0.000 description 2
- GGRLKHMFMUXIOG-UHFFFAOYSA-M 2-acetyloxyethyl(trimethyl)azanium;hydroxide Chemical compound [OH-].CC(=O)OCC[N+](C)(C)C GGRLKHMFMUXIOG-UHFFFAOYSA-M 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 2
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 2
- 244000025254 Cannabis sativa Species 0.000 description 2
- 241000557626 Corvus corax Species 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- 206010020880 Hypertrophy Diseases 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000000205 acacia gum Substances 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 239000012148 binding buffer Substances 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 229910002091 carbon monoxide Inorganic materials 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000007891 compressed tablet Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 2
- 239000008157 edible vegetable oil Substances 0.000 description 2
- 238000003821 enantio-separation Methods 0.000 description 2
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 235000012631 food intake Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000027119 gastric acid secretion Effects 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
- 150000002460 imidazoles Chemical class 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000036316 preload Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 235000019633 pungent taste Nutrition 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000012266 salt solution Substances 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 230000036186 satiety Effects 0.000 description 2
- 235000019627 satiety Nutrition 0.000 description 2
- DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical group CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 229940032147 starch Drugs 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- AFWKWIITHYTPFT-UHFFFAOYSA-N tert-butyl 3-isocyanobenzoate Chemical compound CC(C)(C)OC(=O)C1=CC=CC([N+]#[C-])=C1 AFWKWIITHYTPFT-UHFFFAOYSA-N 0.000 description 2
- SFFFYEGVQDWTNQ-UHFFFAOYSA-N tert-butyl 3-nitrobenzoate Chemical compound CC(C)(C)OC(=O)C1=CC=CC([N+]([O-])=O)=C1 SFFFYEGVQDWTNQ-UHFFFAOYSA-N 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- UCPYLLCMEDAXFR-UHFFFAOYSA-N triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 description 2
- MPDDTAJMJCESGV-CTUHWIOQSA-M (3r,5r)-7-[2-(4-fluorophenyl)-5-[methyl-[(1r)-1-phenylethyl]carbamoyl]-4-propan-2-ylpyrazol-3-yl]-3,5-dihydroxyheptanoate Chemical compound C1([C@@H](C)N(C)C(=O)C2=NN(C(CC[C@@H](O)C[C@@H](O)CC([O-])=O)=C2C(C)C)C=2C=CC(F)=CC=2)=CC=CC=C1 MPDDTAJMJCESGV-CTUHWIOQSA-M 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical group NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- CDGUEDBBMRZLEE-UHFFFAOYSA-N 1h-1,5-benzodiazepin-3-amine Chemical compound N1=CC(N)=CNC2=CC=CC=C21 CDGUEDBBMRZLEE-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- CSDSSGBPEUDDEE-UHFFFAOYSA-N 2-formylpyridine Chemical compound O=CC1=CC=CC=N1 CSDSSGBPEUDDEE-UHFFFAOYSA-N 0.000 description 1
- JHUUPUMBZGWODW-UHFFFAOYSA-N 3,6-dihydro-1,2-dioxine Chemical compound C1OOCC=C1 JHUUPUMBZGWODW-UHFFFAOYSA-N 0.000 description 1
- NXTNASSYJUXJDV-UHFFFAOYSA-N 3-nitrobenzoyl chloride Chemical compound [O-][N+](=O)C1=CC=CC(C(Cl)=O)=C1 NXTNASSYJUXJDV-UHFFFAOYSA-N 0.000 description 1
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 description 1
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 244000144725 Amygdalus communis Species 0.000 description 1
- 235000011437 Amygdalus communis Nutrition 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 229940122737 CCK B receptor agonist Drugs 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical compound NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 1
- IEKOTSCYBBDIJC-UHFFFAOYSA-N N(2)-(3,4-dichlorobenzoyl)-N,N-dipentyl-alpha-glutamine Chemical compound CCCCCN(CCCCC)C(=O)C(CCC(O)=O)NC(=O)C1=CC=C(Cl)C(Cl)=C1 IEKOTSCYBBDIJC-UHFFFAOYSA-N 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 240000006474 Theobroma bicolor Species 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- WERKSKAQRVDLDW-ANOHMWSOSA-N [(2s,3r,4r,5r)-2,3,4,5,6-pentahydroxyhexyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO WERKSKAQRVDLDW-ANOHMWSOSA-N 0.000 description 1
- MIOPJNTWMNEORI-MHPPCMCBSA-N [(4r)-7,7-dimethyl-3-oxo-4-bicyclo[2.2.1]heptanyl]methanesulfonic acid Chemical compound C1C[C@]2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-MHPPCMCBSA-N 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 230000000578 anorexic effect Effects 0.000 description 1
- 230000001663 anti-spastic effect Effects 0.000 description 1
- 239000003699 antiulcer agent Substances 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000000010 aprotic solvent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000000305 astragalus gummifer gum Substances 0.000 description 1
- 125000003310 benzodiazepinyl group Chemical group N1N=C(C=CC2=C1C=CC=C2)* 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 229960000935 dehydrated alcohol Drugs 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000003684 drug solvent Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- HCPOCMMGKBZWSJ-UHFFFAOYSA-N ethyl 3-hydrazinyl-3-oxopropanoate Chemical compound CCOC(=O)CC(=O)NN HCPOCMMGKBZWSJ-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 239000003629 gastrointestinal hormone Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 125000005908 glyceryl ester group Chemical group 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical group [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000005826 halohydrocarbons Chemical class 0.000 description 1
- 230000012447 hatching Effects 0.000 description 1
- 238000000703 high-speed centrifugation Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 229960001021 lactose monohydrate Drugs 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 230000003910 liver physiology Effects 0.000 description 1
- 229950000165 lorglumide Drugs 0.000 description 1
- 208000020442 loss of weight Diseases 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000013289 male long evans rat Methods 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- OFXSXYCSPVKZPF-UHFFFAOYSA-N methoxyperoxymethane Chemical compound COOOC OFXSXYCSPVKZPF-UHFFFAOYSA-N 0.000 description 1
- DZNKOAWEHDKBEP-UHFFFAOYSA-N methyl 2-[6-[bis(2-methoxy-2-oxoethyl)amino]-5-[2-[2-[bis(2-methoxy-2-oxoethyl)amino]-5-methylphenoxy]ethoxy]-1-benzofuran-2-yl]-1,3-oxazole-5-carboxylate Chemical compound COC(=O)CN(CC(=O)OC)C1=CC=C(C)C=C1OCCOC(C(=C1)N(CC(=O)OC)CC(=O)OC)=CC2=C1OC(C=1OC(=CN=1)C(=O)OC)=C2 DZNKOAWEHDKBEP-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 231100001160 nonlethal Toxicity 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- XYEOALKITRFCJJ-UHFFFAOYSA-N o-benzylhydroxylamine Chemical compound NOCC1=CC=CC=C1 XYEOALKITRFCJJ-UHFFFAOYSA-N 0.000 description 1
- 229940100691 oral capsule Drugs 0.000 description 1
- 239000007935 oral tablet Substances 0.000 description 1
- 229940096978 oral tablet Drugs 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- AHWALFGBDFAJAI-UHFFFAOYSA-N phenyl carbonochloridate Chemical compound ClC(=O)OC1=CC=CC=C1 AHWALFGBDFAJAI-UHFFFAOYSA-N 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- QIIPQYDSKRYMFG-UHFFFAOYSA-N phenyl hydrogen carbonate Chemical compound OC(=O)OC1=CC=CC=C1 QIIPQYDSKRYMFG-UHFFFAOYSA-N 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- DBABZHXKTCFAPX-UHFFFAOYSA-N probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 description 1
- 229960003081 probenecid Drugs 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 210000001187 pylorus Anatomy 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 238000001525 receptor binding assay Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 229960004016 sucrose syrup Drugs 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000009492 tablet coating Methods 0.000 description 1
- 239000002700 tablet coating Substances 0.000 description 1
- YGIRNXMYJLWFLH-UHFFFAOYSA-N tert-butyl 3-aminobenzoate Chemical compound CC(C)(C)OC(=O)C1=CC=CC(N)=C1 YGIRNXMYJLWFLH-UHFFFAOYSA-N 0.000 description 1
- LYDRKKWPKKEMNZ-UHFFFAOYSA-N tert-butyl benzoate Chemical compound CC(C)(C)OC(=O)C1=CC=CC=C1 LYDRKKWPKKEMNZ-UHFFFAOYSA-N 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N urea group Chemical group NC(=O)N XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 238000003828 vacuum filtration Methods 0.000 description 1
- 239000003799 water insoluble solvent Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/12—1,5-Benzodiazepines; Hydrogenated 1,5-benzodiazepines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
An enantiomerically enriched compound of Formula (I) is disclosed, processes for its preparation, pharmaceutical compositions containing it and the use therefore, for the treatment of CCK-A mediated diseases or conditions, such as obesity.
Description
The present invention relates to newly 1,5-benzodiazepine derivative, its preparation method, contain their medicinal compositions and the application in medical science thereof.More particularly, the present invention relates to the CCK-A acceptor is shown the compound of agonist activity.
Cholecystokinin (CCK) is the peptide of finding in gi tract and central nervous system.See A.J.Prange etc., Ann.Reports Med.Chem.17,31,33 (1982), J.A.Williams, Biomed Res, 3,107 (1982) and V.Mutt, Gastrointestinal Hormones, G.B.J.Green, Ed., Raven Press, N.Y., 169.Found that CCK especially can be used as the full sense of physiological (satiety) hormone that participates in appetite stimulator, see Della-Ferra etc., Science.206,471 (1979), Satio etc., Nature, 289,599 (1981), G.P.Smith, Eating and ItsDisorders, A.J.Stunkard and E.Stellar, Eds., Raven Press, New York, 67 (1984), as the conditioning agent of gall-bladder contraction and pancreas enzyme secretion, stomach emptying inhibitor and as neurotransmitter, see A.J.Prange, the same, J.A.Williams, Biomed Res, 3,107 (1982); J.E.Morley, Life Sci, 30,479, (1982).Gastrin relates to the peptide of hydrochloric acid in gastric juice and pepsinia in the stomach, sees L.Sandvik etc., American J.Physiology, 260, G925 (1991), C.W.Lin etc., American J.Physiology, 262, G1113 (1992).CCK and gastrin are at the terminal tetrapeptide of their C-: have same structure among the Trp-Met-Asp-Phe.
Identify two kinds of hypotypes of cck receptor, be called CCK-A and CCK-B, in periphery and central nervous system, all found two kinds of hypotypes.Report CCK-B acceptor and gastrin acceptor are similar recently, see Pisegna, J.R., de Weerth, A, Huppi, K.Wank, S.A., Biochem.Biophys.Res.Commun.189,296-303 (1992).The CCK-A acceptor mainly is arranged in peripheral tissues, comprises that pancreas, gall-bladder, ileum, pyloric sphincter and fan walk afferent neurofibers; Find that the CCK-A acceptor seldom is present in the brain, sees T.H.Moran etc., Brain Res., 362,175-179 (1986), D.R.Hill etc., Brain Res., 4545,101 (1988), D.R.Hill etc., Neurosci Lett., 89,133 (1988), R.W.Barret etc., Mol.Pharmacol., 36,285, (1989), D.R.Hill etc., J.Neurosci., 10,1070 (1990), V.Dauge etc., Pharmacol Biochem Behac, 33,637 (1989), and the CCK-B acceptor mainly is found in the brain, see V.J.Lotti and R.S.L Chang, Proc.Natl.Acad.Sci.U.S.A., 83,4923 (1986), J.N.Crawley etc., Trends Pharm.Sci., 88,232 (1991).
The CCK agonist activity is relevant with the picked-up of inhibition animal foodstuff, therefore can reduce body weight, sees Della-Fera etc., and is the same, K.E.Asin etc., Intl.Conference on Obesity, summary pp.40 (1990).Think that CCK walks fibre-effects in periphery by the fan, do not directly act on brain and produce full sense, see Smith G.P. and Cushin, B.J., Neuroscience Abstr., 4,180 (1978), Smith G.P., Jerome, C., Cushin, B.J., Eterno, R. and Simansky, K.J., Science, 212,687-689 (1981).
U.S. Patent No. 5,646,140 (Sugg etc.) disclose some 3-amino-1,5-benzodiazepine compound, these compounds present agonist activity to mammiferous CCK-A acceptor, therefore can make it regulate hormone gastrin and cholecystokinin (CCK).See the compound of embodiment 7 for details.Some this compounds also presents antagonistic activity to the CCK-B acceptor.
In brief, on the one hand, the invention provides formula (I) compound or its pharmacy acceptable salt or the solvate that are rich in enantiomorph.
Formula (I) compound is 3-{3-[1-(sec.-propyl-phenyl-carbamyl ylmethyl)-2,4-dioxo-5-phenyl-2,3,4,5-tetrahydrochysene-1H-benzo [b] [1,4] diaza -3-yl]-urea groups } phenylformic acid.This compound has chiral carbon on benzodiazepine ring.The applicant finds preferably have the enantiomorph of forward opticity under the condition of following explanation.According to Cahn Ingold Prelog rule, this enantiomorph that below is referred to as (+) enantiomorph has (S) configuration.The applicant finds that this ratios of the isomers racemic mixture has better character, therefore is more suitable for the disease and the illness of treatment of obesity and other CCK-A mediation than racemic mixture.The present invention's used " being rich in enantiomorph " is meant the raceme mixture with respect to each isomer with equivalent, and (+) enantiomorph is more than (-) enantiomorph.The present invention's used " The compounds of this invention " or " compound of enantiomorph is rich in the present invention " and contain these or the expression of similar phrase all comprise its pharmacy acceptable salt or solvate." (+) enantiomorph " refers to the optics rotation of enantiomorph, rather than refers to its salt and solvate thereof.Preferred salt and solvate are the salt and the solvate of this formula (I) compound (+) enantiomorph, and no matter the rotation of the optics of this salt or solvate.
Preferably (+) enantiomorph accounts for this and is rich at least 90% of enantiomeric compounds total amount.More preferably (+) enantiomorph accounts at least 96% of this total amount of compound.Most preferably (+) enantiomorph accounts at least 99% of this total amount of compound.
(+) of the present invention enantiomorph presents the CCK-A agonist activity, and can be identified as be a kind of agonist of cholecystokinin completely, its can with the CCK-A receptors bind, in animal test model (paradigms), can stimulate gall-bladder to shrink comprehensively and reduce diet.For example, (+) of the present invention mapping physical efficiency is indirectly by reducing body weight or directly induce the delay stomach emptying by CCK-A, and is used for treatment of obesity and associated conditions, as hypertension, stasis gallbladder disease and diabetes.In addition, (+) disclosed by the invention enantiomorph is Mammals (especially people) modulation of appetite, treatment is fat and keep loss of weight, and the new approach that brings out the satiety sense, appetite stimulator and change food absorption are provided is provided.
Therefore, the present invention provides the disease of the CCK-A mediation for the treatment of Mammals (comprising the people) or the method for symptom on the other hand, and it comprises (+) the of the present invention enantiomorph that gives the patient treatment significant quantity.
On the other hand, the invention provides the present invention is rich in the compound of enantiomorph or its pharmacy acceptable salt or solvate and is used for the treatment of purposes in the medicine of the disease of CCK-A mediation or illness in preparation.
Those skilled in the art are clear: treatment comprises the definite disease or the prevention and the treatment of symptom referred in this.In addition, need be clear that: the amount that is used for the treatment of needed preferred enantiomorph of the present invention will be decided according to the character of treatment disease and patient's age and the state of an illness, finally by doctor in charge or animal doctor's decision.But the general used dosage of adult treatment is generally 0.02-5 every day, and the scope of 000mg is as 1-1500mg.Ideal dosage is generally with single dose or with the divided dose of appropriate intervals administration, as every day two, three, four or sub-doses form repeatedly existing more favourable.
Though in treatment, can give the compound that enantiomorph is rich in the present invention, preferably give this active ingredient with the medicinal compositions form with the chemical feedstocks form.Therefore, the present invention also provides medicinal compositions, and it comprises that the present invention is rich in the compound of enantiomorph and one or more pharmaceutically acceptable carrier and/or vehicle, and other optional component that treats and/or prevents.Therefore said carrier and/or vehicle must be " acceptable ", and its meaning is and other component compatibility of preparation and harmless to its acceptor.
Preparation of the present invention comprises that those make in oral, the oral cavity specially, the preparation of non-enteron aisle, implantation, part or rectal administration, but the preferred oral administration.For oral administration, composition can be mixed with tablet or lozenge form according to common method.Oral tablet or capsule can comprise vehicle commonly used, as tackiness agent (as syrup, gum arabic, gelatin, sorbyl alcohol, tragacanth gum, starch mucus or polyvinylpyrrolidone), weighting agent (as lactose, sugar, Microcrystalline Cellulose, W-Gum, calcium phosphate or sorbyl alcohol), lubricant (as Magnesium Stearate, stearic acid, talcum powder, polyoxyethylene glycol or silica gel), disintegrating agent (as yam starch or sodium starch glycollate) or wetting agent, as sodium lauryl sulphate.Can with tablet coating, comprise enteric coating according to method well known in the art.
In addition, the preferred enantiomorph of the present invention can be made oral liquid, as water-based or oiliness suspensoid, solution, emulsion, syrup or elixir.In addition, the preparation that contains these preferred enantiomorphs can be the drying products form, and water or other suitable solvent are made solution again before use for they.These liquid preparations can contain additive commonly used, as suspension agent, and for example sorbitol syrups, methylcellulose gum, glucose/sucrose syrup, gelatin, Natvosol, carboxymethyl cellulose, aluminium stearate gel or hydrogenated edible oil; Emulsifying agent, for example Yelkin TTS, sorbitol monooleate or gum arabic; (it can comprise water-insoluble solvent
Edible oil) as Prunus amygdalus oil, rectifying peanut oil, grease class, polyoxyethylene glycol or ethanol; And sanitas, as the methyl or the propyl diester of P-hydroxybenzoic acid or Sorbic Acid.Also these preparations can be mixed with suppository, as, suppository base commonly used contained, for example the suppository of theobroma oil or other glyceryl ester.
In addition, the present composition can be mixed with formulation by the injection or the parenterai administration of continuous infusion.Injection can adopt in the suspensoid of water-based or oiliness solvent, solution or emulsion form, and can contain formulation excipients, as suspension agent, stablizer and/or dispersion agent.In addition, this active ingredient can adopt and face the powder type that is mixed with liquid with the suitable solvent of preceding usefulness (as aseptic, apirogen water) again.
Also the present composition can be mixed with and store agent (depot).These prolonged action preparations can be by implanting (as subcutaneous or intramuscular) or giving by intramuscular injection.Therefore, preferred enantiomorph of the present invention and suitable polymer or the derivative (as the salt of indissoluble) of hydrophobic materials (for example, at the emulsion that can accept in the oil), ion exchange resin or poorly water-soluble can be mixed with preparation.
The present composition can contain the active ingredient of 0.1-99%, and general tablet and capsule contain the active ingredient of 30-95%, and liquid dosage form contains the active ingredient of 3-50%.
(+) of the present invention enantiomorph can at first be made racemic mixture by the method for 7 explanations of embodiment in the United States Patent (USP) 5,646,140, then by the preparation of chiral chromatography enantiomer separation.
Perhaps; described (+) enantiomorph can pass through suitable enantiomorph; be (the S)-enantiomorph of formula (II) amine: (wherein R is a carboxyl-protecting group with the isocyanic ester of formula (III); as the tertiary butyl), (wherein R is a carboxyl-protecting group to formula (IV) imidazoles; as the tertiary butyl) or (wherein R is a carboxyl-protecting group to choose the formula V carbonic acid phenyl ester that replaces wantonly; as the tertiary butyl, R
1Be hydrogen or conventional phenyl substituent, as NO
2) reaction, remove carboxyl-protecting group R then and prepare.
This reaction in the presence of appropriate solvent such as ether (as tetrahydrofuran (THF)) or halohydrocarbon (as methylene dichloride) or nitrile (as acetonitrile), is carried out in 0-80 ℃ of temperature range expediently.
The enantiomorph of required amine (II) can use the form of its salt, as the R-camsilate, in this embodiment, can exist down at alkali (as tertiary amine, as triethylamine), carries out this reaction.
The hydrolysis of carboxyl-protecting group can adopt ordinary method to carry out.(Protecting?groups?inOrganic?Synthesis?T.Greene,Ed,Wiley?Interscience,New?York,p168,1981)。Therefore, for example when R is the tertiary butyl, can adopt definite method, by with suitable acid, this protecting group is removed in example hydrochloric acid, trifluoroacetic acid or formic acid hydrolysis.For example in solvent (as 1, the 4-dioxane) with hydrochloric acid reaction, perhaps heating is down removed protecting group with the formic acid reaction in solvent such as acetone or aqueous acetone solution.
(the S)-enantiomorph of required formula (II) amine:
Can split corresponding racemic amine preparation by chirality HPLC chromatography, perhaps bring out asymmetric fractionation preparation by the R camsilate.
Racemic amines (II) can be by the method preparation of explanation in the intermediate 11 of United States Patent (USP) 5,646,140.
In addition, the reduction when racemic amines (II) can pass through oxime (VI) and hydrogenolysis preparation, wherein R
2It is the optional benzyl that replaces.
This reaction in ethanol, Virahol or industrial methylated spirit or tetrahydrofuran (THF), in the presence of the hydrogen or the ammonium formiate aqueous solution, is adopted suitable palladium catalyst expediently at solvent such as alkanol, carries out as palladium on carbon (on the 5%Pd/ gac).This is reflected at heating down, and is as 40-80 ℃, more favourable as carrying out under 60 ℃.
The suitable R that uses in the reaction
2Example comprise the benzyl of benzyl or replacement, as to methoxy-benzyl or diphenyl-methyl.
Oxime (VI) can pass through adjacent phenylenediamine derivative (VII):
With the activity derivatives reaction preparation of diacid (VIII), wherein R
2It is the optional benzyl that replaces.
The reactive derivative of diacid (VIII) generally is two corresponding carboxylic acid halides, and as muriate, it can be by this diacid (VIII) and oxalyl halogen (as oxalyl chloride) prepared in reaction.This reaction in aprotic solvent such as ester (as ethyl acetate), toluene, methylene dichloride, dimethoxy ether and composition thereof, is carried out in the presence of dimethyl formamide easily.
This diacid (VIII) in the presence of alkali (as pyridine), makes ketone group dialkyl malonate (as the ketone group diethyl malonate) and corresponding azanol R easily by in solvent such as alkanol (as ethanol or industrial methylated spirit)
2ONH
2React, adopt aqueous sodium hydroxide solution that corresponding oximido dialkyl malonate hydrolysis is prepared then.
On the other hand, the invention provides method with (the S)-enantiomorph of formula (I) compound of above-mentioned racemic amines (II) preparation essentially no (R) enantiomorph, wherein this racemic amines (II) is prepared by oxime (VI) as mentioned above, more particularly, wherein oxime (VI) prepares by compound (VII) with (VIII).
Formula (III) isocyanic ester can be buied, perhaps can be in appropriate solvent such as methylene dichloride, and the amine (VI) by correspondence is in phosgene or triphosgene prepared in reaction.Can be under the temperature of 0-80 ℃ of scope (easily at room temperature), in appropriate solvent (methylene dichloride, ether, tetrahydrofuran (THF)), by handling corresponding amine (VI) with carbonyl dimidazoles, but preparation formula (IV) imidazoles.Can under 0-50 ℃ temperature, in appropriate solvent (methylene dichloride), in the presence of alkali (pyridine, triethylamine),, can prepare the carboxylamine phenylester of the optional formula V that replaces by making corresponding amine (VI) and the optional chloroformic acid phenylester reaction that replaces.Formula (VI) amine is compound known, can be by those used similar method preparations of preparation known compound.
Adopt the following example explanation the present invention, the present invention is not done any qualification.
In an embodiment, abbreviation EtOAc=ethyl acetate; MeOH=methyl alcohol; DMF=N, dinethylformamide; The IPA=Virahol; The IMS=industrial methylated spirit.
Intermediate 1
(+)-2-(3-amino-2,4-dioxo-5-phenyl-2,3,4,5-tetrahydro benzo-[b] [1,4] diaza -1-
Base)-N-sec.-propyl-phenyl acetanilide,Phenacetylaniline camsilate
In tetrahydrofuran (THF) (35ml) and toluene (65ml), will (+/-)-2-(3-amino-2,4-dioxo-5-phenyl-2,3,4,5-tetrahydro benzo-[b] [1,4] diaza -1-yl)-and N-sec.-propyl-phenyl acetanilide,Phenacetylaniline (10g) and R-camphorsulfonic acid (4.98g) stirring, obtain solution.This solution is heated to 70 ℃, forms suspension.Toluene (5ml) solution that adds entry (0.4ml), 2-pyridylaldehyde (0.24g) in turn.This mixed solution was heated 3 hours down at 70 ℃, be cooled to 25 ℃ with 5 hours then, stirred 16 hours down at 25 ℃.With suspension be cooled to 0-5 ℃ following 1.5 hours.Solid collected by filtration (10ml) is washed with toluene/tetrahydrofuran (THF) (2: 1).Obtain title compound 50 ℃ of following vacuum-dryings, be white solid (12.6g).Chromatographic analysis: eluent: 30% Virahol, 70% heptane+0.05% diethylamine; Post: 25cm * 4.6mm internal diameter, Chiralpak AD; Flow velocity: 1ml/ minute; Temperature: 40 ℃; Detect: UV230nm; Volume injected: 10 μ L; Sample solution: 0.1mg/ml; Sample is dissolved in 30% Virahol, 70% heptane.Injection immediately after the sample solution preparation.Retention time: (+) enantiomorph, 8.2 minutes.Unwanted (-) enantiomorph (12.7 minutes) is lower than detectability.
Intermediate 2
3-nitrobenzoic acid tertiary butyl ester
Potassium tert.-butoxide (3.82g) is joined in anhydrous tetrahydro furan (70ml) solution of 3-nitrobenzoyl chloride (5.00g), under nitrogen, stirred 2 hours.The vacuum concentration reaction mixture distributes between methylene dichloride and water then.Separate each phase, water layer is returned with ethyl acetate again carry then.Merge organic layer,, filter, then vacuum concentration through anhydrous magnesium sulfate drying.Crude product is through quick level silica gel purification, with the normal hexane liquid gradient elution of 0-5% ethyl acetate.Merge the part that contains product, vacuum concentration, dry under the high vacuum then, obtain title compound, be oily matter (3.82g).
1H?NMR(300MHz,CDCl
3)。δ=1.63(s,9H);7.62(t,J=7.9Hz,1H);8.29-8.41(m,2H);8.78-8.80(m,1H)。MS(Cl):[M+H]
+=224。
Intermediate 3
3-amino-phenylformic acid tertiary butyl ester
(10wt%, 0.30g), stir about is 3 hours under hydrogen with dehydrated alcohol (50ml) solution of 3-nitrobenzoic acid tertiary butyl ester (3.77g) and palladium on carbon.By diatomite layer filtering reaction mixed solution, vacuum concentration obtains oily matter then, and crystallization when dry obtains title compound under high vacuum, is brown solid (3.28g).
1H?NMR(300MHz,CDCl
3)δ=1.58(s,9H);6.79-6.87(m,1H);7.19(t,J=8.5Hz,1H);7.24-7.34(m,1H);7.38(d,J=8.0Hz,1H)。MS(Cl):[M+H]
+=194。
Intermediate 4
3-isocyano--phenylformic acid tertiary butyl ester
Under 0-5 ℃, triphosgene (13.428g) is joined in anhydrous tetrahydro furan (600ml) solution of 3-benzaminic acid tertiary butyl ester (26.50g) and triethylamine (38.23ml).Under 0-5 ℃, reaction mixture was stirred 2 hours, vacuum concentration obtains white solid then.Crude product is stirred slurry in hexane (500ml), filter, vacuum concentrated filtrate obtains title compound, is oily matter (21.54g, 71.6%).This crude product isocyanic ester need not be further purified and can directly use.
1H?NMR(300MHz,CDCl
3)δ=1.59(s,9H);7.23(bd,J=7.8Hz,1H);7.36(t,J=7.8Hz,1H);7.69(bs,1H);7.81(d,J=7.8Hz,1H)。
Intermediate 5
(+)-3-{3-[1-(sec.-propyl-phenyl-carbamyl ylmethyl)-2,4-dioxo-5-phenyl-2,3,4,5-
Tetrahydrochysene-1H-benzo [b] [1,4] diaza -3-yl]-urea groups } the phenylformic acid tertiary butyl ester
Method A
With intermediate (1; 66.30g) slowly join in anhydrous tetrahydro furan (750ml) solution of 3-isocyano--phenylformic acid tertiary butyl ester (21.54g).In reaction mixture, drip triethylamine (13.70ml).Under the room temperature, the reaction mixture stirring that obtains is spent the night.Reaction mixture is poured in the water (3000ml), obtained white solid.Solid collected by filtration, water (3 * 500ml) washings.The vacuum filtration drying obtains title compound, is white solid (65.01g).This crude product title compound need not be further purified and can directly use.Chromatography feature: eluent: 30% Virahol, 70% heptane+0.05% diethylamine; Post: 25cm * 4.6mm internal diameter, ChiralpakAD; Flow velocity: 1ml/ minute; Temperature: 40 ℃; Detect: UV 230nm; Volume injected: 10 μ L; Sample solution: the 0.1mg/ml sample in 30% Virahol, 70% heptane.Injection immediately after the sample solution preparation.Retention time: (+) enantiomorph, 15.6 minutes.Unwanted (-) enantiomorph (13.3 minutes) is lower than detectability.
Method B
In 20 ℃ of carbonyl dimidazoles (13.2g) suspensions in methylene dichloride (55ml) that stir down, with methylene dichloride (40ml) solution that dripped 3-benzaminic acid tertiary butyl ester (15.8g) in 30 minutes.Under 20 ℃, with the solution stirring that obtains 1 hour.With methylene dichloride (130ml) solution that adds intermediate 1 (50g) in 5 fens this solution of clockwise.Add entry (200ml) quencher reaction solution, stirred 10 minutes.Separate each phase, organic phase is washed with water.Under atmospheric pressure concentrate organic phase, the 100ml methylene dichloride is removed in distillation.Add t-butyl methyl ether (700ml), under 20 ℃, the mixture stirring is spent the night.Solid collected by filtration, with t-butyl methyl ether (100ml) washing, 45 ℃ of following vacuum-dryings, obtain title compound, for white solid (42g, 63mmol).
Intermediate 6
The 2-[(benzyloxy) imino-] diethyl malonate
Under 20 ℃, ketone group diethyl malonate (60g) is joined in the suspension of O-benzyl hydroxylamine (57.8g) in the IMS that contains pyridine (30ml) (500ml) of stirring.Under 75 ℃, with reaction solution heating 4 hours.With reaction solution cooling, removal of solvent under reduced pressure.Residue is distributed between EtOAc (500ml) and water (300ml), separate organic layer, water (250ml) washing is through MgSO
4Dry.Evaporating solvent obtains title compound 95.3g, for colorless oil (yield 99%, the residual EtOAc of about 3%w/w), need not be further purified and can directly use.
1H?NMR(300MHz,CDCl
3)7.4(m,5H),5.35(s,2H),4.35(m,4H),1.3(m,6H)。
Intermediate 7
The 2-[(benzyloxy) imino-] propanedioic acid
With 20 minutes, in the MeOH of intermediate 6 (40g) (80ml) solution, add 2M NaOH (200ml).Under the room temperature, reaction solution was stirred 2 hours.MeOH is removed in decompression, drips dense HCl (about 30ml), and residual solution is acidified to pH2.Cool off during this time to keep temperature to be lower than 35 ℃.Form dense white soup compound, water (50ml) dilution is flowed helping.Solid collected by filtration with cold water (25ml) washing, 55 ℃ of following vacuum-dryings, obtains title compound (17g), is white solid, finds to contain the residual inorganic salt of the 10%w/w that has an appointment in the product.Yield corrected is about 45%, need not be further purified and can directly use.
1H?NMR(300MHz,D
2O)7.4(m,5H),5.2(s,2H)。
Intermediate 8
The 2-[3-[(benzyloxy) imino-]-2,4-dioxo-5-phenyl-2,3,4,5-tetrahydrochysene-1H-1,5-benzo two
The azatropylidene base)-N-sec.-propyl-phenyl acetanilide,Phenacetylaniline
Oxalyl chloride (38.3g) is dripped (about 1 hour), and (0.5ml is in the suspension among EtOAc 5mol%) (200ml) containing DMF to the intermediate 7 that stirs (40g proofreaies and correct salts contg to 31.4g).Under 25 ℃, mixed solution was stirred 0.5 hour, filter by the Dicalite layer then, with EtOAc (40ml) washing, obtain clarifying yellow solution.Under 25 ℃, this solution is joined in N-sec.-propyl-N-phenyl-2-(2-phenyl amino the phenyl amino)-pulpous state liquid of ethanamide (50g) in EtOAc (120ml) of stirring.Mixture is warmed to 60 ℃, forms deep purple solution.After 1 hour, remove EtOAc (200ml) by the normal atmosphere distillation.Add IPA (120ml) and water (40ml), more more solvent (80ml) is further removed in the mixed solution distillation and added IPA (40ml) and water (40ml), the solvent (80ml) of other amount is removed in redistillation.With 1.5 hours, reaction mixture is cooled to 25 ℃, solid collected by filtration.With this solid with IPA (2 * 120ml), water (1 * 120ml) and use again at last IPA (1 * 40ml) washing, 55 ℃ of following vacuum-dryings, obtain title compound then, be orange red powder (56.6g).
1H NMR (300MHz, CDCl
3) 2: 1 isomer mixture 7.6-6.95 of this oxime (m, 18H), 6.9 (t, 1H), 5.3 (m, 2H), 4.95 (m, H), 4.65 (d, 0.33H), 4.4 (d, 0.67H), 4.1 (d, 0.67H), 4.0 (d, 0.33H), 0.95 (m, 6H).
Intermediate 9
(±)-2-(3-amino-2,4-dioxo-5-phenyl-2,3,4,5-tetrahydro benzo-[b] [1,4] diaza -1-
Base)-N-sec.-propyl-phenyl acetanilide,Phenacetylaniline
In the suspension of the IMS (30ml) of intermediate 8 (3g) that stirs and ammonium formiate (2.08g) and water (3ml), adding 5%Pd/C (50%w/w water) (0.25g).Under nitrogen, with mixture 60 ℃ of following heated overnight.Filter this hot reaction mixture to remove catalyzer by Dicalite.Catalyzer with hot IMS (60ml) washing, is filtered.Concentrating under reduced pressure filtrate obtains title compound, is white solid (2.34g).
Embodiment 1
The chromatography of enantiomorph splits
(+) and (-)-3-{3-[1-(sec.-propyl-phenyl-carbamyl ylmethyl)-2,4-dioxo-5-phenyl-
2,3,4,5-tetrahydrochysene-1H-benzo [b] [1,4] diaza -3-yl]-urea groups } phenylformic acid
Press United States Patent (USP) 5, the method of embodiment 7 explanations prepares racemic 3-{3-[1-(sec.-propyl-phenyl-carbamyl ylmethyl)-2 in 646,140,4-dioxo-5-phenyl-2,3,4,5-tetrahydrochysene-1H-benzo [b] [1,4] diaza -3-yl]-urea groups } phenylformic acid, under the following conditions, split: 250 * 4.0 μ m (internal diameter) posts, 5 μ m Diacel Chiracel OD-R by chirality HPLC; Eluent is 80: 20: 0.1: 1,80 part of acetonitrile, 20 parts of water, 0.1 part of triethylamine and 1 part of acetate; It is 230nm that UV detects wavelength; Temperature is that room temperature flow rate is 1ml/min; Volume injected is 20 μ L.Under these conditions, (+) enantiomorph retention time is 6.50 minutes, and (-) isomer retention time is 3.89 minutes.
Embodiment 2
(+)-3-{3-[1-(sec.-propyl-phenyl-carbamyl ylmethyl)-2,4-dioxo-5-phenyl-2,3,4,5-
Tetrahydrochysene-1H-benzo [b] [1,4] diaza -3-yl]-urea groups } phenylformic acid
Method A
Under the room temperature; with (+)-3-{3-[1-(sec.-propyl-phenyl-carbamyl ylmethyl)-2; 4-dioxo-5-phenyl-2; 3; 4; 5-tetrahydrochysene-1H-benzo [b] [1,4] diaza -3-yl)-and urea groups } phenylformic acid tertiary butyl ester (intermediate 5:65.01g) stirred 6 hours in the dioxane (280ml) of 4N hydrochloric acid.With the reaction mixture vacuum concentration, the solid/oily matter that obtains is ground in water, obtain white solid.Filter and collect white solid, water (2 * 500ml) washings.Crude product is dissolved in the hot acetone (250ml), adds entry (275ml) until the solution becomes muddiness.Add acetone (40ml) again, this solution is heated to obtains settled solution.This solution is placed cooling.Filter and collect the white solid that obtains, and water (3 * 100ml) washings, dry in vacuum (20-25Hg) chamber under 40-50 ℃, obtain title compound, be white solid (40.496g).Through chirality chromatography (seeing that chromatogram splits scheme) purity analysis.Specific rotation (0.712g is in the 100mL acetone soln) [α]
D=+84.3.
1H?MR(300MHz,DMSO)δ=0.95(d,J=7.5Hz,3H);0.97(d,J=7.2Hz,3H);4.18(d,J=16.7Hz,1H);4.48(d,J=16.7Hz,1H);4.78(m,1H);5.02(d,J=7.8Hz,1H);6.91(d,J=7.8Hz,1H);6.95(bd,J=8.1Hz,1H);7.22-7.57(m,19H);8.00(s,1H);9.34(s,1H);12.78(s,1H)。MS(ES):[M+1]=606.1;[M+Na]=628.1;[M-1]=604.1。
Method B
Under the room temperature, intermediate 5 (5g) is joined in the mixed solution of acetone (15ml) and formic acid (25ml), the suspension that obtains is heated to 50 ℃ and stirred 5 hours.In this solution, drip entry (30ml), and keep the content temperature more than 50 ℃.Under 55 ℃, the soup compound that obtains was stirred 1 hour, be cooled to room temperature, stirring is spent the night.This soup compound is filtered water (3 * 25ml) washings.Residue is joined among the IMS (50ml), this soup compound is heated to 45 ℃, stirring is spent the night.Soup compound is cooled to room temperature, filters, under 55 ℃,, obtain title compound, be white solid (3.40g) this wet cake vacuum drying.
The required product of this reaction of chiral chromatography analysis revealed contains unwanted (-)-enantiomorph of 0.7%.
Medicine embodiment
Oral liquid
Active ingredient 0.5-800mg
Poly(oxyethylene glycol) 400 NF is in right amount to 50ml
Active ingredient is suspended in the poly(oxyethylene glycol) 400, and ultrasonic dissolution is made oral liquid then.
Oral administration mixed suspension
Active ingredient 0.5-80mg
Polysorbate80 NF (tween 80) 0.02ml
The aseptically filling water is in right amount to 20ml
Active ingredient is joined in 0.1% (v/v) the tween 80 solution (20ml), and oral administration mixed suspension is made in the ultrasonic or jolting with mixed solution then.
Tablet
a.
Active ingredient 6mg
Lactose hydrous USP 136.2mg
Sodium starch glycollate USP/NF 6mg
Stearic acid USP/NF 1.5mg
Colloid silica USP/NF 0.3mg
Compressed tablet weight 150mg
Active ingredient, lactose and sodium starch glycollate are sieved by 590 tm screen, suitably mixing in the mixing tank.Add stearic acid (sieving) and hand over body silicon-dioxide, mix with activated mixture by 250 tm screen.Use suitable stamping machine, in flakes with this mixture compacting.
b.
Active ingredient 6mg
Microcrystalline Cellulose USP/NF 136.5mg
Cross-linked polyvinylpyrrolidone USP/NF 6mg
Magnesium Stearate USP/NF 1.5mg
Compressed tablet weight 150mg
Active ingredient, Microcrystalline Cellulose and cross-linked polyvinylpyrrolidone are sieved by 590 tm screen, suitably mixing in the mixing tank.Screening Magnesium Stearate (by 250 tm screen) mixes with activated mixture.With suitable tablet stamping machine, that the mixture compacting that obtains is in blocks.
Capsule
a.
Active ingredient 6mg
Microcrystalline Cellulose USP/NF 128.25mg
Sodium starch glycollate USP/NF 15mg
Magnesium Stearate USP 0.75mg
Filling weight 150mg
Active ingredient, Microcrystalline Cellulose and sodium starch glycollate are sieved by 590 tm screen, be mixed together, lubricate with the Magnesium Stearate that sieves by 250 tm screen then.Mixture is filled in the capsule of proper volume.
b.
Active ingredient 6mg
Lactose monohydrate USP 130.5mg
Polyvinylpyrrolidone USP 6mg
Cross-linked polyvinylpyrrolidone NF 6mg
Magnesium Stearate 1.5mg
Filling weight 150mg
Active ingredient and lactose are mixed together, granulate with polyvinylpyrrolidonesolution solution.The material drying that this is wetting is ground.Magnesium Stearate and cross-linked polyvinylpyrrolidone are screened by 250 tm screen, mix with this particle.The mixture that obtains is filled in the hard gelatin capsule of proper volume.
Physiological Experiment
By following experimental identification (+) and (-) enantiomorph and racemic modification.Summarize these test-results in the following table.
The preparation of cavy gallbladder tissue is from using CO
2Take out gall-bladder in the male Hartley cavy that gas is put to death.Adherent reticular tissue in the isolating gall-bladder of flush away is cut into two rings (2-4mm is long) from each animal gall-bladder.Ring is suspended in contains normal saline solution (118.4mM NaCl, 4.7mM KCl, 1.2mM MgSO
4, 2.5mM CaCl
2, 1.2mM KH
2PO
3, 25mMNaHCO
3, 11.1mM glucose) have in the cabinet, this body lotion is remained under 37 ℃, charge into 95%O
2/ 5%CO
2To keep pH=7.4.By gold chain and stainless steel metal wire, on power such as tissue is connected to displacement transmitter (Grass, Model FT03D).Then with response record on polygraph (Grass, Model 7E).The portion tissue of getting each animal is as time/solvent control, and this tissue is handled without test compound.To encircle gradually the basic rest tension that elongation (through 120 fens clock times) keeps 1gm to the whole test.Regulating between basic tension period, ring is exposed to vagusstoff (10
-6M) four shrinkabilitys to confirm to organize.Then this tissue is exposed to CCK-8 vitriol (Sigma, 3 * 10 of inferior maximal dose
-9M) in.After obtaining stable response, in 1 hour every 5-10 minute, will organize washing fast 3 times with the reconstruction of stability baseline.
Agonist EC
50Value is dissolved in compound in the methyl-sulphoxide (DMSO), dilute with water then, by accumulative total concentration-response curve to test compound (10
-11To 3 * 10
-5M) measure, then in the presence of the maximum concentration test compound, by the concentration-response curve to CCK-8 vitriol (10
-10-10
-6M) measure.At last, add vagusstoff (1mM) and bring out maximum collapse.Each test compound is minimum to carry out three determinations of activity.
The foundation of the stable clone that has cck receptor is with human body CCK-A
18Or CCK-B
19CDNA clone be connected in the pcDNA1-novel vector (derive from Invitrogen Corp, San Diego carry out direct transfection in CA).Prepare DNA by the molten born of the same parents' method of alkalescence, adopt then lipofection reagent (Gibco BRL, Gaithersberg, MD) transfection to the CHO-K1 cell (ATCC, Rockville, MD) on.Adopt Geneticin (Gibco BRL) to select stable transfection at first, by with fluorescein-Gly-[(Nle28,31)]-and CCK-8 is combined into the fluorescence activity cell of basic sorting, and enrichment has the resistant cell of acceptor.Then, establish clone system by the limit dilution process.
The cytolemma preparation is at 37 ℃, humid atmosphere (95%O2/5%CO
2) under, in the HamShi F12 substratum that is supplemented with 5% heat inactivation ox tire serum, make CHO-K1 cell growth through people CCK-A or CCK-B receptor cdna stable transfection.With passage 2 times, grow to 2-4 * 10 weekly
6The density of cell/mL.Centrifugal (600xg, 15 minutes, 4 ℃) collecting cell, be resuspended to then the damping fluid that contains TrisHCl (25mM), EDTA (5mM), EGTA (5mM), benzene sulfonyl fluorine (0.1mM) and soybean insulin inhibitor (100 μ g/mL) (20mL, pH7.4) in.With motorize glass teflon refiner (25 amplitude) ruptured cell, that homogenate low speed (600xg, 10 minutes, 4 ℃) is centrifugal.Collect supernatant liquor, high speed centrifugation (500,000xg, 15 minutes, 4 ℃) precipitation specific part.The low speed precipitation is carried out 3 times again.Merge ultracentrifugal specific part, it is (in the 1-5mg protein/mL), freezing down at-80 ℃ to be resuspended to damping fluid.Adopting BioRad reagent and bovine serum albumin is standard substance, measures protein concn according to manufacturer's specification sheets.
Receptor binding assays will
125(Amersham 2000Ci/mmol) is dissolved in and contains HEPES (20mM), NaCl (118mM), KCl (5mM), MgCl I-Bolton Hunter CCK-8
2(5mM) and in the binding buffer liquid of EGTA (1mM) (pH7.4,100,000cpm/25 μ L).Use MK-329
20(10 μ M, CCK-A) and L-365,260
21(10 μ M CCK-B), measure non-specific binding.Deposit concentration with 100 times of whole experimental concentration is dissolved in test compound among the DMSO, is diluted to suitable concentration with binding buffer liquid then in titer plate.With 96-hole titer plate, carry out combination test in triplicate, in titer plate, add in turn then test compound (25 μ L),
125I-Bolton Hunter CCK-8 (25 μ L), damping fluid (pH7.4,150 μ L) and acceptor prepare liquid (50 μ L).In all test holess, the final concentration of DMSO is 1%.30 ℃ after following 3 hours, by mixture being filtered to fast on the glass filter (Whatman GF/B), stop hatching, continuous washing is removed unconjugated part.By gamma counter, the bonded radioactivity is carried out quantitatively.
Being determined on the glass cover slide of cellular calcium makes the CHO-K1 cell through hCCK-A or hCCK-B acceptor stable transfection grow to the 75-90% fusion.With 50 minutes, this cell is filled in the serum free medium that contains 5mM FURA2-AM and 2.5mM probenecid.By standard ratio meter technology, adopt the excitation wavelength of 340nm and 380nm, use the variation of JASCO CAF-102 calcium analysis-e/or determining cellular calcium concentration.With CCK-8 (n=2) that increases concentration or compound (n=2) perfusion cell, until the ratio platform that reaches 340/380.Between continued stimulus, allow flushing/time of recovery of at least 10 minutes.Peak response is normalized to CCK-8 inductive peak response.The EC at half desired concn place of peak response is induced in calculating
50Value.Except that agonist concentration-response curve, with the compound (10 of three concentration
-8, 10
-7, 10
-6M, n=2) the CHO-K1 cell of perfusion expressing human CCK-B acceptor is 1 hour, obtains CCK-8 (10 then
-12To 10
-6M) concentration-response curve.
The apocleisis test: with male Long-Evans rat (225-300g) fasting 2 hours, (Bio-Serve F1657, Frenchtown NJ), made it adapt to for two weeks to the good to eat liquid food of feeding then.In the day of pre-treatment, with rat fasting (100 minutes), IP injectable drug solvent (propylene glycol, PG, 1mL/kg) and oral give load (preload) salt solution (0.9%NaCl, 8mL/kg).Provide liquid food after 20 minutes, located to measure consumption at 30,90 and 180 minutes.For qualitative to drug treating research, within 30 minutes of day of pre-treatment, rat must consume 8mL liquid food at least.Next day, after the fasting 100 minutes, through IP or PO give rat (each dosage 8-10 animal) solvent (PG, 1mL/kg) or various dosage (0.01-10 μ mol/kg) be dissolved in test compound among the PG (1mL/kg), oral immediately then preload salt solution.After 20 minutes, provide food again, located to measure food intake at 30,90 and 180 minutes.From pre-treatment, the data normalization of every rat food intake is worth to each.Potential when measuring 30 minutes and 30 minutes, the usefulness under the 1 μ mol/kg dosage.n
The test of mouse gall-bladder round: Makovec, F.; Bani, M.; Cereda, R.; Chiste, R.; Pacini, M.A.; Revel, L; Rovati, L.C. is to the antispastic activity (Lorglumide) of CR1409 mouse gall-bladder, effective antagonistic action of periphery cholecystokinin, Pharmacol.Res.Commun.1987,19,41-51.
The pharmacology contrast of enantiomorph and racemic modification
Test | (+) enantiomorph | (-) enantiomorph | Racemic modification |
External | |||
GPGBEC 50(nM) | 9.3 | 63 | 40 |
HCCK-AIC 50(nM) | 148 | 191 | 123 |
HCCK-AEC 50(nM) | 150 | 298 | 252 |
HCCK-BK i(nM) | 3.2 | 22.3 | 10 |
HCCK-BEC 50(nM) | Antagonist | Antagonist | Antagonist |
Select than 1 | 46 | 8.6 | 12.3 |
PApp(×10 -7cm/sec) | 1.6 | 0.7 | |
In the body | |||
The rat apocleisis | |||
ED 50IP(μmol/kg) | 0.034 | 0.48 | 0.06 |
ED 50PO(μmol/kg) | 1.1 | Non-activity 3 | 2.0 |
The test of mouse gall bladder emptying | |||
ED 50IP(μmol/kg) | 0.002 | 0.012 | 0.007 |
ED 50PO(μmol/kg) | 0.007 | Non-activity 2 | 0.055 |
1. select ratio=IC
50(hCCK-A)/K
i(hCCK-B)
2. non-activity is the highest can be to 10 μ mol/kg
3. when dosage is up to 10 μ mol/kg, does not observe diet and obviously reduce.
PApp value: adopt Artursson P. and Karlson J.1991, Biochem.Biophys Res.Common.175, the intestines infiltration is measured in the in vitro tests of 880-885 (relation in absorption of human body oral pharmaceutical and human gut epithelial (CACO-2) cell between the apparent drug osmotic coefficient).
Three kinds of unexpected physiologically actives will make a distinction between (+) enantiomorph and (-) enantiomorph and the racemic modification.Wherein two kinds of activity relate to the effectiveness that strengthens CCK-A, and this effectiveness should be improved the useful activity of this enantiomorph.The third is active relevant with the CCK-B antagonistic activity of (+) enantiomorph, and it can improve helpfulness by reducing toxicity.
In the cavy gall-bladder test (" GPGB ") of in-vitro separation, the effect of (+) enantiomorph is than 4 times of racemize heights.In mouse gall bladder emptying test (oral administration), the effect of (+) enantiomorph is than 8 times of racemize heights.The increase of predicting this usefulness is useful to the treatment of stasis gallbladder and obesity, because stasis gallbladder is the key issue that body weight reduces fast.
Anoretic plans therefore must have extremely low toxicity risk for life-time service.Using relevant main toxicity with cholecystokinin is the CCK-B receptor agonist activity of following.The activity of CCK-B acceptor is main relevant with the increase of anxiety and gastric acid secretion.Explored and utilized CCK-B antagonist exploitation antianxiety agent and anti ulcer agent.See, for example, Lowe, J, " cholecystokinin-B receptor antagonist (Cholecystokinin-B Receptor Antagonists) " in Exp.Opin.Ther.Patents, 5 (3), pp 231-237 (1995).
Topmost cck receptor hypotype is the CCK-A hypotype in the rodent pancreas, and the intensity of activation of this hypotype is brought out the high pungency and the hypertrophy of pancreas in the rodent.Think that now these two kinds of activity all are undesirable.Reported the tissue distribution of cck receptor in the tissue recently.Be that topmost receptor subtype is the CCK-B receptor subtype in people's pancreas astoundingly.See, for example, Wank, S.A, " cholecystokinin receptor " in American Journal ofPhysiology-Gastrointestinal ﹠amp; Liver Physiology, 32 (5):, pp G628-G646 (1995).Therefore, in human body, the activation of CCK-B acceptor (CCK-B agonist activity) can be brought out the increase of anxiety and gastric acid secretion, and life-time service also can bring out the high pungency and the hypertrophy of pancreas.
For reducing the danger of unwanted CCK-B agonist activity in the body, preferred compound reply CCK-B acceptor has affinity, and has the CCK-B antagonistic activity that can measure in vitro tests.Two kinds of enantiomorphs and racemic modification all are the CCK-B antagonists.Though these three kinds of compositions all have similar human body CCK-A receptor affinity (IC
50) and validity (EC
50), but (+) enantiomorph has the highest CCK-B receptor affinity (IC
50) and selectivity (46 times).Therefore, with regard to the minimum potentiality of the toxic side effects of bringing out with regard to CCK-A potential and validity and CCK-B, preferred (+) enantiomorph.
Under the useful dosage of treatment, (+) of the present invention enantiomorph is avirulent basically.For example, in single oral dose research, the maximum non-lethal dose of finding rat is greater than 2000mg/kg, and male mice is greater than 1000mg/kg, and female mice is greater than 500mg/kg.
Claims (10)
1. be rich in the 3-{3-[1-(sec.-propyl-phenyl-carbamyl ylmethyl)-2 of enantiomorph; 4-dioxo-5-phenyl-2; 3; 4; 5-tetrahydrochysene-1H-benzo [b] [1; 4] diaza -3-yl]-urea groups } phenylformic acid, or its pharmacy acceptable salt, wherein (+) enantiomorph or its pharmacy acceptable salt account at least 90% of described compound.
2. the compound that is rich in enantiomorph of claim 1, wherein (+) enantiomorph or its pharmacy acceptable salt account at least 96% of described compound.
3. claim 1 or 2 the compound that is rich in enantiomorph, wherein (+) enantiomorph or its pharmacy acceptable salt account at least 99% of described compound.
4. medicinal compositions, it comprises among the claim 1-3 with one or more pharmaceutically acceptable carrier and/or mixed with excipients each the compound that is rich in enantiomorph.
5. each compound is used for the treatment of purposes in the medicine of the disease of CCK-A mediation or illness in preparation among the claim 1-3.
6. the purposes of claim 5, wherein said disease or illness are obesity, stasis gallbladder disease or diabetes.
7. the purposes of claim 5, wherein said disease or illness are obesity.
8. method for preparing the compound of claim 1, this method comprises:
(a) 3-[3-[1-(sec.-propyl-phenyl-carbamyl ylmethyl)-2 by chirality HPLC resolution of racemic, 4-dioxo-5-phenyl-2,3,4,5-tetrahydrochysene-1H-benzo [b] [1,4] diaza -3-yl] phenylformic acid; Or
(b) make (the S)-enantiomorph of formula (II) amine:
With the isocyanic ester of formula (III), the imdazole derivatives of formula (IV) or the phenyl carbamate reaction of formula V,
R wherein
1Be H or NO
2, R is a carboxy protective group;
Remove carboxy protective group R then.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9910366.5 | 1999-05-06 | ||
GBGB9910366.5A GB9910366D0 (en) | 1999-05-06 | 1999-05-06 | 1,5-Benzodiazepine Derivatives |
GBGB0008179.4A GB0008179D0 (en) | 2000-04-05 | 2000-04-05 | Chemical process |
GB0008179.4 | 2000-04-05 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1362949A CN1362949A (en) | 2002-08-07 |
CN1161345C true CN1161345C (en) | 2004-08-11 |
Family
ID=26244033
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB008099324A Expired - Fee Related CN1161345C (en) | 1999-05-06 | 2000-05-04 | 1,5-benzodiazepine derivatives as cck-A receptor agonists |
Country Status (21)
Country | Link |
---|---|
EP (1) | EP1212305A2 (en) |
JP (1) | JP2002544200A (en) |
KR (1) | KR20020012567A (en) |
CN (1) | CN1161345C (en) |
AR (1) | AR022044A1 (en) |
AU (1) | AU4754800A (en) |
BR (1) | BR0010338A (en) |
CA (1) | CA2370801A1 (en) |
CO (1) | CO5170461A1 (en) |
CZ (1) | CZ20013988A3 (en) |
HK (1) | HK1046138A1 (en) |
HU (1) | HUP0201181A3 (en) |
IL (1) | IL146124A0 (en) |
MX (1) | MXPA01011267A (en) |
MY (1) | MY138319A (en) |
NO (1) | NO20015397L (en) |
NZ (1) | NZ515048A (en) |
PE (1) | PE20010110A1 (en) |
PL (1) | PL351546A1 (en) |
TR (1) | TR200103169T2 (en) |
WO (1) | WO2000068209A2 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005035793A2 (en) * | 2003-10-09 | 2005-04-21 | Decode Genetics Ehf. | Cckar markers and haplotypes associated with extreme weight conditions |
EP1753766A1 (en) | 2004-05-25 | 2007-02-21 | Pfizer Products Inc. | Tetraazabenzo(e)azulene derivatives and analogs thereof |
CA3156985A1 (en) | 2019-10-07 | 2021-04-15 | Kallyope, Inc. | Gpr119 agonists |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9307833D0 (en) * | 1993-04-15 | 1993-06-02 | Glaxo Inc | Modulators of cholecystokinin and gastrin |
-
2000
- 2000-05-03 AR ARP000102119A patent/AR022044A1/en unknown
- 2000-05-04 IL IL14612400A patent/IL146124A0/en unknown
- 2000-05-04 CA CA002370801A patent/CA2370801A1/en not_active Abandoned
- 2000-05-04 PE PE2000000415A patent/PE20010110A1/en not_active Application Discontinuation
- 2000-05-04 HU HU0201181A patent/HUP0201181A3/en unknown
- 2000-05-04 MY MYPI20001917A patent/MY138319A/en unknown
- 2000-05-04 WO PCT/EP2000/003982 patent/WO2000068209A2/en not_active Application Discontinuation
- 2000-05-04 AU AU47548/00A patent/AU4754800A/en not_active Abandoned
- 2000-05-04 KR KR1020017014075A patent/KR20020012567A/en not_active Application Discontinuation
- 2000-05-04 EP EP00929488A patent/EP1212305A2/en not_active Withdrawn
- 2000-05-04 BR BR0010338-1A patent/BR0010338A/en not_active IP Right Cessation
- 2000-05-04 CN CNB008099324A patent/CN1161345C/en not_active Expired - Fee Related
- 2000-05-04 JP JP2000617189A patent/JP2002544200A/en active Pending
- 2000-05-04 MX MXPA01011267A patent/MXPA01011267A/en not_active Application Discontinuation
- 2000-05-04 PL PL00351546A patent/PL351546A1/en not_active Application Discontinuation
- 2000-05-04 NZ NZ515048A patent/NZ515048A/en unknown
- 2000-05-04 CZ CZ20013988A patent/CZ20013988A3/en unknown
- 2000-05-04 CO CO00031982A patent/CO5170461A1/en not_active Application Discontinuation
- 2000-05-04 TR TR2001/03169T patent/TR200103169T2/en unknown
-
2001
- 2001-11-05 NO NO20015397A patent/NO20015397L/en not_active Application Discontinuation
-
2002
- 2002-10-23 HK HK02107684.4A patent/HK1046138A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP1212305A2 (en) | 2002-06-12 |
TR200103169T2 (en) | 2002-04-22 |
MY138319A (en) | 2009-05-29 |
HUP0201181A3 (en) | 2003-10-28 |
KR20020012567A (en) | 2002-02-16 |
CO5170461A1 (en) | 2002-06-27 |
PL351546A1 (en) | 2003-05-05 |
CA2370801A1 (en) | 2000-11-16 |
IL146124A0 (en) | 2002-07-25 |
NZ515048A (en) | 2004-01-30 |
HK1046138A1 (en) | 2002-12-27 |
NO20015397D0 (en) | 2001-11-05 |
JP2002544200A (en) | 2002-12-24 |
WO2000068209A2 (en) | 2000-11-16 |
CN1362949A (en) | 2002-08-07 |
BR0010338A (en) | 2002-02-13 |
CZ20013988A3 (en) | 2002-02-13 |
HUP0201181A2 (en) | 2002-12-28 |
MXPA01011267A (en) | 2002-05-06 |
NO20015397L (en) | 2001-11-05 |
WO2000068209A3 (en) | 2001-03-01 |
AR022044A1 (en) | 2002-09-04 |
AU4754800A (en) | 2000-11-21 |
PE20010110A1 (en) | 2001-03-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1065536C (en) | Process and crystal form of 2-methyl -thieno -benzodiazepine | |
CN1031051C (en) | Cycloalkyl-substituted glutaramide antihypertensive agents | |
CN1330652A (en) | 2,3,4,4-tetrahydro-1H-pyrazino (1,2-a) quinoxalin-5(6H) one deivatives being 5HT2C agonists | |
CN1234023A (en) | 4-aminoethoxy indoes as dopamin D2 agonists and as 5HT1A ligands | |
CN1201461A (en) | Fused tropane-derivatives as neurotransmitter reuptake inhibitors | |
JPH08119923A (en) | Glycineamide derivative,method of preparing same and medicine containing same | |
CN1053438C (en) | Polysubstituted 3-acylamino-5-phenyl-1,4-benzodiazepin-2-one derivatives, process for their preparation and the pharmaceutical compositions containing them | |
CN1246860A (en) | 3-aryl substituted pyrazolo [4,3-d] pyrimidine derivatives, corticotropin-releasing factor receptor (CRT1) specific ligands | |
CN1509196A (en) | 4(2-butylamino)-2,7-dimethyl-8-(2-methyl(-6-methoxyp-3-yl)pyrazolo-[1,5-A]-1,3,5-triazine as corticotropin releasing factor receptor | |
US20050054635A1 (en) | Cyclohepta[b][1,4]diazepino[6,7,1,-hi]indoles and derivatives | |
CN101511808A (en) | Diaryl ether derivatives and uses thereof | |
CN1150172C (en) | 1,5 benzodiazepine derivatives | |
CN1161345C (en) | 1,5-benzodiazepine derivatives as cck-A receptor agonists | |
CN1059722A (en) | 3-aryl-4 (3H) quinazolinone CCK peptide antagonists and pharmaceutical preparation thereof | |
CN1507437A (en) | Aralkylpiperazines with serotonin 5-HTIA activity | |
CN1264827C (en) | 1-cyclic amino-alkylcyclohexane compounds, pharmaceutical compositions thereof and their use as anticonvulsants | |
CN1370154A (en) | Aminothiazole derivatives and their use as CRF receptor ligands | |
CN1080918A (en) | New aminopropanol derivatives contains their pharmaceutical composition and preparation method thereof | |
CN1335316A (en) | New N-triazolyl methyl piperazine derivate using as neurokinin receptor antagonistic agent | |
CN1414962A (en) | [(Indol-3-yl)-cycloalkyl]-3-substituted azetidines for treatment of central nervous system disorders | |
CN1826344A (en) | (1S,5S)-3-(5,6-dichloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane is an effective analgesic agent | |
CN1430597A (en) | Novel MMP-2/MMP-9 inhibitors | |
CN1120845A (en) | 1,5 benzodiazepine derivatives having CCK and/or gastrin antagonistic activity | |
CN1158615A (en) | Bicyclic carboxamides as 5-ht1A antagonists | |
CN1077890C (en) | 4-aminoethyoxy-indolone derivatives as dopamine D2 agonists |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C06 | Publication | ||
PB01 | Publication | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C19 | Lapse of patent right due to non-payment of the annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |